Unknown

Dataset Information

0

Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials.


ABSTRACT:

Purpose

Dose-limiting neuropathy is a major adverse event associated with most of the microtubule-stabilizing agent-based chemotherapy regimens. Ixabepilone, a semisynthetic analogue of the natural epothilone B, has activity against a wide range of tumor types. Peripheral neuropathy (PN), associated with ixabepilone treatment, is usually mild to moderate, predominantly sensory and cumulative. Preclinical studies demonstrate that ixabepilone and taxanes produce a similar neurotoxicity profile.

Methods

We searched databases of phase II/III clinical trials involving patients receiving ixabepilone as a monotherapy or in combination with capecitabine for incidences of neuropathy. Potential risk factors for grade 3/4 PN were identified by a Cox regression analysis on a dataset of 1,540 patients with different tumor types across multiple studies.

Results

Rates for incidence of ixabepilone-induced severe PN (Common Terminology Criteria for Adverse Events grade 3/4) ranged from 1% in early untreated breast cancer up to 24% in heavily pretreated metastatic breast cancer; grade 4 PN was rare (? 1%). Common symptoms included numbness, paresthesias, and sometimes dysesthesias. Cox regression analysis identified only preexisting neuropathy as a risk factor for increased ixabepilone-associated PN. The management of PN has been primarily through dose adjustments (dose delays and/or dose reduction). Patients had resolution of their neuropathy within a median time of 5 to 6 weeks.

Conclusions

PN is a dose-limiting toxicity associated with ixabepilone treatment, is reversible in most patients, and can be managed with dose reduction and delays.

SUBMITTER: Vahdat LT 

PROVIDER: S-EPMC3461204 | biostudies-literature | 2012 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials.

Vahdat Linda T LT   Thomas Eva S ES   Roché Henri H HH   Hortobagyi Gabriel N GN   Sparano Joseph A JA   Yelle Louise L   Fornier Monica N MN   Martín Miguel M   Bunnell Craig A CA   Mukhopadhyay Pralay P   Peck Ronald A RA   Perez Edith A EA  

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20120302 11


<h4>Purpose</h4>Dose-limiting neuropathy is a major adverse event associated with most of the microtubule-stabilizing agent-based chemotherapy regimens. Ixabepilone, a semisynthetic analogue of the natural epothilone B, has activity against a wide range of tumor types. Peripheral neuropathy (PN), associated with ixabepilone treatment, is usually mild to moderate, predominantly sensory and cumulative. Preclinical studies demonstrate that ixabepilone and taxanes produce a similar neurotoxicity pro  ...[more]

Similar Datasets

| S-EPMC4288236 | biostudies-literature
| S-EPMC4492237 | biostudies-literature
| S-EPMC10322124 | biostudies-literature
| S-EPMC4283755 | biostudies-literature
| S-EPMC5761583 | biostudies-literature
| S-EPMC2803791 | biostudies-literature
| S-EPMC6293634 | biostudies-literature
| S-EPMC8458950 | biostudies-literature
| S-EPMC10286344 | biostudies-literature
| S-EPMC7913382 | biostudies-literature